Acurx Pharmaceuticals LLC

Company Profile

Acurx Pharmaceuticals LLC had its IPO on 2021-06-25 under the ticker symbol ACXP.

The company operates in the Healthcare sector and Biotechnology industry. Acurx Pharmaceuticals LLC has a staff strength of 4 employees.

Stock update

Shares of Acurx Pharmaceuticals LLC opened at $1.72 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.71 - $1.85, and closed at $1.75.

This is a +1.74% increase from the previous day's closing price.

A total volume of 37,374 shares were traded at the close of the day’s session.

In the last one week, shares of Acurx Pharmaceuticals LLC have slipped by -5.41%.

Acurx Pharmaceuticals LLC's Key Ratios

Acurx Pharmaceuticals LLC has a market cap of $43.12 million, indicating a price to book ratio of 4.3934 and a price to sales ratio of 0.

In the last 12-months Acurx Pharmaceuticals LLC’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Acurx Pharmaceuticals LLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Acurx Pharmaceuticals LLC’s operating margin was 0% while its return on assets stood at -55.23% with a return of equity of -95.34%.

In Q3, Acurx Pharmaceuticals LLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Acurx Pharmaceuticals LLC’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Acurx Pharmaceuticals LLC’s profitability.

Acurx Pharmaceuticals LLC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.5195. Its price to sales ratio in the trailing 12-months stood at 0.

Acurx Pharmaceuticals LLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$10.95 million

Total Liabilities

$1.18 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Acurx Pharmaceuticals LLC ended 2025 with $10.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.95 million while shareholder equity stood at $9.76 million.

Acurx Pharmaceuticals LLC ended 2025 with $0 in deferred long-term liabilities, $1.18 million in other current liabilities, 11593.00 in common stock, $-35380574.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.61 million and cash and short-term investments were $10.61 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Acurx Pharmaceuticals LLC’s total current assets stands at $10.95 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.18 million and inventory worth $0.

In 2025, Acurx Pharmaceuticals LLC's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Acurx Pharmaceuticals LLC paid $0 in dividends in 2025.

Other key metrics

Current Trading Price

$1.75

52-Week High

$4.85

52-Week Low

$2.33

Analyst Target Price

$13.33

Acurx Pharmaceuticals LLC stock is currently trading at $1.75 per share. It touched a 52-week high of $4.85 and a 52-week low of $4.85. Analysts tracking the stock have a 12-month average target price of $13.33.

Its 50-day moving average was $2 and 200-day moving average was $3.02 The short ratio stood at 1.04 indicating a short percent outstanding of 0%.

Around 2118.1% of the company’s stock are held by insiders while 1176.5% are held by institutions.